The Cytometry Core provides flow and image cytometry and cell sorting instrumentation, expertise, training, consultation, and other services to Case Comprehensive Cancer Center (Case CCC) investigators. There are two sites, one at Case and one at the Lerner Research Institute, that work together under a Federation Model. These two sites, under one Case CCC administration, provide efficient maximization of resources and providing uniform quality of services to all cancer investigators. The resource serves a base of approximately 170 laboratories in any one year and a broader base over time. Services include consulting, training/teaching, low, intermediate, and high-end (multi-laser, multi-color) cytometry, low and high speed cell sorting and single cell deposition (cloning), multilaser/multicolor laser scanning cytometry, absolute cell counting, data analysis, and specialized staining. Services are delivered in styles to fit individual need, ranging from independent use of instruments to fully dependent, sample drop-off mode. Instruments are upto- date and the Core has been the beneficiary of multiple Shared Instrumentation Grants. Core usage has increased at both sites, growing at 13% per year over the last 5 years (data from Case). The core is used by 8 of the 9 programs of the Case CCC with the heaviest use in programs 2, 3, 6, and 7 (Cell Proliferation and Cell Death, Radiation and Cellular Stress Response, Stem Cells and Hematologic Malignancies, and Developmental Therapeutics, respectively), and the developing Vascular Biology initiative. Peer-reviewed cancer member use is high. Case CCC members receive discounted service.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-20
Application #
7799300
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
20
Fiscal Year
2009
Total Cost
$340,518
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266
Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182
Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151
Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:
Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643

Showing the most recent 10 out of 1227 publications